Timing is everything
for some patients

Accelerate PhenoTest™ BC Kit –

A recent customer study showed identification and susceptibility results with MICs an average of 42 hours faster than their standard of care.*

*Data on file, manuscript in preparation
90 min
identification
7 hr
susceptibility
 

Admitted Sunday.
MIC results Monday.

The Accelerate PhenoTest™ BC Kit makes earlier optimal therapy possible by providing answers, directly from positive blood cultures, that drive treatment decisions 1-2 days faster than current methods allow today.

Earlier optimal therapy can lead to reduced cost of patient care, fewer adverse incidents, lower rate of resistance, and better clinical outcomes.

Clinical relevancy

Timely escalation to effective therapy reduces mortality

Impact of Time to Definitive Therapy on Mortality4
Empiric therapy may not be adequate in up to 25% of patients with bloodstream infections (BSIs).4 Shortening the time horizon from empiric to optimal therapy requires susceptibility results with the MIC for 52% of patients with BSIs.5

4 Retamar et al. Antimicrob Agents Chemother. 2012 Jan;56(1):472-8
5 Huang et al. Clin Infect Dis. 2013 Nov;57(9):1237-45

Timely escalation to effective therapy reduces hospital length of stay

Impact of Effectiveness of Antibiotic on Hospital Length of Stay (Gram-negative sepsis)6
Reducing hospital length of stay (LOS) by two days reduces broad spectrum antibiotic exposure that may increase the risk of HAIs, C. difficile infection, and increase risk of community-acquired resistance. It also substantially reduces cost of care.

6 Shorr et al, Crit Care Med 2011. Jan; 39(1): 46-51

De-escalation can improve patient outcomes

% CDI Incidence by Number of Simultaneous Drug Classes Administered

Reducing the time frame from empiric broad-spectrum antibiotic coverage to optimal therapy has been shown to dramatically reduce the incidence of C. difficile in patients with BSIs.7

Reporting antimicrobial susceptibility results 1-2 days faster gives clinicians the data required to move to targeted optimal therapy faster.

7 Tartof et al, 2015. Infect. Control Hosp. Epidemiol. 2015;36(12) :1409–1416

Sensible economics

Potential economic impact across a hospital system serviced by a centralized microbiology lab*
$4.8k
net savings per patient tested
1.7k
fewer ICU days
each year
$10.8m
net financial impact to hospital system
*Estimated healthcare outcome and economic impact based on model of first full year of testing on positive blood culture samples.
Walk me through this

Gram-Positive

Identification
Ampicilin
Ceftaroline
Doxycycline
Erythromycin
Trimetheoprim-
Sulfamethoxazole
Daptomycin
Linezolid
Vancomycin
MRSA
(Cefoxitin)
MLSb
(Erythromycin-
Clindamycin)
S. aureus
S. lugdunensis
CoNS spp.
E. faecalis
E. faecium
Streptococcus spp.
S. agalactiae
S. pneumoniae
Resistance
Phenotypes
S. aureus S. lugdunensis CoNS spp. E. faecalis E. faecium Streptococcus spp. S. agalactiae S. pneumoniae
Identification
Ampicilin
Ceftaroline
Doxycycline
Erythromycin
Trimetheoprim-Sulfamethoxazole
Daptomycin
Linezolid
Vancomycin
MRSA (Cefoxitin)
Resistance Phenotypes
MLSb (Erythromycin-Clindamycin)

  Future development

Gram-Negative

Identification
Ampicillin-
Sulbactam
Piperacillin-
Tazobactam
Cefazolin
Cefepime
Ceftazidime
Ceftriaxone
Ertapenem
Meropenem
Amikacin
Gentamicin
Tobramycin
Ciprofloxacin
Minocycline
Aztreonam
Colistin
E. coli
Klebsiella spp.
Enterobacter spp.
Proteus spp.
Citrobacter spp.
S. marcescens
P. aeruginosa
A. baumannii
E. coli Klebsiella spp. Enterobacter spp. Proteus spp. Citrobacter spp. S. marcescens P. aeruginosa A. baumannii
Identification
Ampicillin-
Sulbactam
Piperacillin-
Tazobactam
Cefazolin
Cefepime
Ceftazidime
Ceftriaxone
Ertapenem
Meropenem
Amikacin
Gentamicin
Tobramycin
Ciprofloxacin
Minocycline
Aztreonam
Colistin

Yeast

Identification
Candida albicans
Candida glabrata
 

Klebsiella spp.
K. oxytoca
K. pneumoniae

Enterobacter spp.
E. cloacae
E. aerogenes

Proteus spp.
P. mirabilis
P. vulgaris

Citrobacter spp.
C. freundii
C. koseri

CoNS spp.
S. capitis
S. epidermidis
S. haemolyticus
S. hominis
S. lugdunensis
S. warneri

Streptococcus spp.
S. agalactiae
S. gallolyticus
S. mitis
S. oralis
S. pneumoniae

E. faecium
Enterococcus spp.
other than
E. faecalis

Specifications

48-channel disposable test cassette
Reagent cartridge
Sample vial

The Accelerate PhenoTest™ BC kit is run directly with positive blood culture samples.
Store BC kits at 2-8°C. Do not store at room temperature.

1 Kit

Dimensions:
2.5 h x 8 w 12 l in
6.2 h x 20 w x 30 l cm

Weight:
2.1 lb
950 g

Storage: 2.8°C

5 Pack, including packaging

Dimensions:
13 h x 12.5 w x 13 l in
33 h x 32.5 w x 33 l cm

Weight:
33 lb
15 kg

Publications

May 26, 2017

Automated microscopy for rapid directed antibiotic treatment of sepsis
ISICEM 2017

May 26, 2017

Evaluation of the Accelerate Pheno™ system for fast identification and antimicrobial susceptibility testing from positive blood culture in Gram-negative bloodstream infection

May 22, 2017

Evaluation of Accelerate Pheno™ System in a Clinical Setting: Comparison of Identification and Antibiotic Susceptibility Test Results of 224 Prospective Positive Blood Cultures to Standard Laboratory Methods at Detroit Medical Center
ECCMID 2017

May 22, 2017

Predicting the hVISA Phenotype Using a Novel in vitro Real-time Assessment of S. aureus Division Rates
ECCMID 2017

See all publications